ANIP:NSD-ANI Pharmaceuticals Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 28.89

Change

0.00 (0.00)%

Market Cap

USD 0.37B

Volume

0.30M

Avg Analyst Target

USD 60.00 (+107.68%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota. Address: 210 Main Street West, Baudette, MN, United States, 56623

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-18 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
CGC Canopy Growth Corporation

N/A

USD5.80B N/A N/A
TLRY Tilray Inc

N/A

USD5.40B N/A N/A
PCRX Pacira BioSciences Inc

N/A

USD2.49B 14.52 22.71
CRON Cronos Group Inc

N/A

USD2.22B 37.00 N/A
ORGO Organogenesis Holdings Inc

N/A

USD2.02B 28.11 21.47
IRWD Ironwood Pharmaceuticals Inc

N/A

USD2.01B 3.94 9.52
DVAX Dynavax Technologies Corporati..

N/A

USD1.71B N/A 86.33

ETFs Containing ANIP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.52% 65% D 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.52% 65% D 37% F
Trailing 12 Months  
Capital Gain -4.84% 48% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.84% 48% F 20% F
Trailing 5 Years  
Capital Gain -54.68% 50% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.68% 50% F 12% F
Average Annual (5 Year Horizon)  
Capital Gain -5.92% 38% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.92% 38% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 32.51% 75% C 56% F
Risk Adjusted Return -18.21% 35% F 12% F
Market Capitalization 0.37B 57% F 46% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 77.58 10% F 14% F
Price/Book Ratio 1.86 69% D+ 64% D
Price / Cash Flow Ratio 24.15 6% F 19% F
EV/EBITDA 15.75 45% F 47% F
Management Effectiveness  
Return on Equity -8.99% 75% C 45% F
Return on Invested Capital -3.12% 74% C 42% F
Return on Assets 0.26% 75% C 46% F
Debt to Equity Ratio 88.12% 25% F 24% F
Technical Ratios  
Short Ratio 8.41 31% F 16% F
Short Percent 5.16% 61% D- 34% F
Beta 1.26 51% F 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector